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Abstract
Nucleoside analogs represent the backbone of several distinct chemotherapy regimens
for acute myeloid leukemia (AML) and combination with tyrosine kinase inhibitors has
improved survival of AML patients, including those harboring the poor‐risk FLT3‐ITD
mutation. Although these compounds are effective in killing proliferating blasts, they
lack activity against quiescent leukemia stem cells (LSCs), which contributes to initial
treatment refractoriness or subsequent disease relapse. The reagent 8‐chloro‐adenosine
(8‐Cl‐Ado) is a ribose‐containing, RNA‐directed nucleoside analog that is incorporated
into newly transcribed RNA rather than in DNA, causing inhibition of RNA transcription.
In this report, we demonstrate antileukemic activities of 8‐Cl‐Ado in vitro and in vivo
and provide mechanistic insight into the mode of action of 8‐Cl‐Ado in AML. 8‐Cl‐Ado
markedly induced apoptosis in LSC, with negligible effects on normal stem cells.
8‐Cl‐Ado was particularly effective against AML cell lines and primary AML blast
cells harboring the FLT3‐ITD mutation. FLT3‐ITD is associated with high expression of
miR‐155. Furthermore, we demonstrate that 8‐Cl‐Ado inhibits miR‐155 expression
levels accompanied by induction of DNA‐damage and suppression of cell proliferation,
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through regulation of miR‐155/ErbB3 binding protein 1(Ebp1)/p53/PCNA signaling.
Finally, we determined that combined treatment of NSG mice engrafted with FLT3‐ITD+
MV4−11 AML cells with 8‐Cl‐Ado and the FLT3 inhibitor AC220 (quizartinib)
synergistically enhanced survival, compared with that of mice treated with the
individual drugs, suggesting a potentially effective approach for FLT3‐ITD AML patients.
K E YWORD S
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1 | INTRODUCTION
Acute myeloid leukemia (AML) patients carrying the fms‐related
tyrosine kinase 3 (FLT3)‐internal tandem duplication (ITD) have a
poor prognosis (Gilliland & Griffin, 2002; Konig & Levis, 2015;
Lagunas‐Rangel & Chávez‐Valencia, 2017; Swords, Freeman, &
Giles, 2012). Nucleoside analogs (NAs) are the backbone of several
upfront and salvage chemotherapy regimens for AML, including
FLT3‐ITD (Jordheim, Durantel, Zoulim, & Dumontet, 2013; Mayer
et al., 1994; Robak & Robak, 2013). Combination of chemotherapy
with tyrosine kinase inhibitors (TKIs) has improved survival of
these patients, but a large proportion of them still die of their
disease. Although these agents have significant antileukemic
activity, they are not effective in eradicating leukemia stem cells
(LSCs), the likely reason for treatment failures in AML. Conse-
quently, new strategies are needed to improve the outcome for this
and other molecular subsets of AML patients.
The reagent 8‐chloro‐adenosine (8‐Cl‐Ado) is a ribose‐containing,
RNA‐directed NA (Gandhi et al., 2001; Stellrecht, Ayres, Arya, & Gandhi,
2010; Stellrecht, Rodriguez, Ayres, & Gandhi, 2003) which, different
from other NAs, is incorporated into newly transcribed RNA rather than
in DNA, as is the case for many other NAs. Treatment with 8‐Cl‐Ado in
a variety of human cancer cells results in inhibition of RNA transcription
and malignant cell growth and survival (Gandhi et al., 2001; Krett et al.,
1997; Stellrecht et al., 2003; 2010; 2017; Stellrecht, Vangapandu,
Le, Mao, & Shentu, 2014; Zhu, Zhang, Zhao, Cui, & Strada, 2006). The
anticancer activity of 8‐Cl‐Ado is dependent on intracellular conversion
of the parent drug into the 8‐Cl‐AMP metabolite, which is subsequently
phosphorylated into 8‐Cl‐ATP (Gandhi et al., 2001). Preliminary in vivo
studies (in animals and in patients with chronic lymphocytic leukemia
[CLL]) showed favorable pharmacokinetic (PK) and pharmacodynamic
(PD) profiles and limited toxicity for 8‐Cl‐Ado (Gandhi et al., 2002 and
unpublished data).
As 8‐Cl‐Ado is incorporated in RNA rather than DNA, it may
have cell cycle‐independent antileukemic activity and be effective
in AML blasts, including subpopulations enriched for LSCs.
microRNA‐155 (miR‐155) is the most overexpressed microRNA
(miRNA) in FLT3‐ITD and reportedly plays a key role in FLT3‐ITD
blast hyper‐proliferation (Khalife et al., 2015; Whitman et al.,
2010). Thus, silencing of miR‐155 has been proposed as a novel
therapeutic approach for FLT3‐ITD AML (Khalife et al., 2015).
As 8‐Cl‐Ado is incorporated mainly into RNA, we reasoned that it
could also be incorporated into miR‐155 (and other miRNAs). In
this report, we show that 8‐Cl‐Ado possesses antileukemic activity
in vitro and in vivo. Moreover, we report that 8‐Cl‐Ado interacts
with and downregulates miR‐155 expression, associated with de‐
regulation of the miR‐155/ErbB3 binding protein 1(Ebp1)/p53/
PCNA signaling pathway. Finally, we show that 8‐Cl‐Ado syner-
gizes with the FLT3 inhibitor AC220 (quizartinib) in growth
inhibition of FLT3‐ITD+ AML cells in vitro and in vivo, thus
suggesting a potentially effective approach for the treatment of
FLT3‐ITD+ AML patients.
2 | MATERIALS AND METHODS
An extensive description of the methods can be found in the
Supporting Information Methods.
2.1 | Patient samples
Bone marrow (BM) and peripheral blood samples from AML
patients or healthy donors were obtained under a specimen
banking protocol approved by the Institutional Review Board of
City of Hope National Medical Center (COH IRB #14269), in
accordance with assurances filed with and approved by the
Department of Health and Human Services and meeting all
requirements of the Declaration of Helsinki. For drug sensitivity
scoring (DSS), AML patient or healthy donor samples (mono-
nuclear cells from BM or peripheral blood) were collected after
written informed consent and ethical approval of the Institutional
Review Board at Helsinki University Central Hospital, Department
of Hematology, as previously described (see Pemovska et al., 2013
in Supporting Information references).
2.2 | Animal experiments
Animal care and experimental procedures were performed
in accordance with approved protocols from the Institutional
Animal Care and Use Committee at the City of Hope National
Medical Center. All animal studies were performed in accordance
with the guidelines of the City of Hope Research Animal Care
Committee.
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2.3 | Statistical analysis
Where indicated, to compare the means of two groups, results were
generally compared by using unpaired, two‐tailed Student’s t test,
with values from at least two independent experiments with
triplicate determination. Data are presented as mean ± standard
error (SE), as indicated. The log‐rank test was used to compare
the survival distributions of the different treatment groups, from
the time of cancer cell injection to the death of the animals. N = 5–8
per group for the animal experiments. p < 0.05 was considered
statistically significant; ns indicates not significant. All statistical
analyses were conducted using SigmaPlot 12.5 (Systat Software,
Chicago, IL). All statistical tests were two‐sided.
3 | RESULTS
3.1 | Antileukemic effects of 8‐CL‐Ado in AML cells
To test the antileukemic activity of 8‐Cl‐Ado in AML, we first
evaluated two representative AML cell lines, FLT3‐ITD+ MV4–11
and FLT3 WT KG‐1a, by treating with 10 μM 8‐Cl‐Ado for 12 hr.
We measured intracellular concentrations of the 8‐Cl‐ATP tripho-
sphate metabolite, which reached 680–870 μM, and found a
concurrent 20–22% decrease in endogenous levels of ATP, in
contrast to vehicle‐treated controls (p < 0.05; Figure 1a). Accumu-
lation of 8‐Cl‐Ado triphosphate and 8‐Cl‐Ado‐dependent depletion
of endogenous cellular ATP pools were also observed in lympho-
cytes from CLL patients treated with 8‐Cl‐Ado (Stellrecht et al.,
2017). Exposure to increasing concentrations of 8‐Cl‐Ado
(0.1–100 μM) for 72 hr resulted in significant dose‐dependent
inhibition of cell growth, with IC50 values in the sub‐ to low‐
micromolar range (Figure 1b). 8‐Cl‐Ado increased the apoptosis
rate only in FLT3‐ITD+ cells (MV4–11; Figure 1c) but not in FLT3
WT cells (KG‐1a, THP1, HL‐60; Figure 1d). Cell cycle analysis
demonstrated that 8‐Cl‐Ado‐induced G0/G1 arrest and decreased
proteins involved in cell cycle regulation, including cyclins A2 and
E2, CDC25a, and CDK2 (Figures 1e and S1). Of note, 8‐Cl‐Ado
increased the sub‐G0/G1 peak and the apoptosis rate only in
FLT3‐ITD+ cells (Figure 1e).
3.2 | FLT3‐ITD+ AML sensitivity to 8‐Cl‐Ado
Among AML primary blasts from patients with distinct cytogenetic
and molecular subtypes of AML (n = 11) and hematopoietic stem
cells (HSCs) from healthy donors, those harboring activating FLT3
mutations (both FLT3‐ITD and FLT3‐TKD; Figure 2a, top) had the
F IGURE 1 Antileukemic activities of 8‐Cl‐Ado in AML cell lines. (a) Intracellular concentrations of 8‐Cl‐ATP and ATP in MV4–11 (FLT3‐ITD+)
and KG‐1a (FLT3 WT) cells (2 × 105 cells/ml) treated with 10 µM 8‐Cl‐Ado for up to 12 hr. N = 2, data are presented as mean ±SE, with triplicate
determination. (b) Effect of 8‐Cl‐Ado on the proliferation of (2 × 105 cells/ml) leukemic cells (KG‐1a: FLT3 WT; MV4–11, MOLM‐14, OCI‐AML3,
MOLM‐13: FLT3‐ITD+) treated with increasing concentrations of 8‐Cl‐Ado for 72 hr. N = 2, data are presented as mean±SE, with quadruplicate
determination. (c and d) Effect of 8‐Cl‐Ado on apoptosis of leukemic cells. (c) MV4–11 and KG‐1a cells (2 × 105 cells/ml) were treated with up to
10 µM 8‐Cl‐Ado for 24 hr. (d) FLT3WT cells (2 × 105 cells/ml; HL‐60, THP1, KG‐1a), and FLT3‐ITD+ cells (MV4–11) were treated with 500 nM 8‐
Cl‐Ado for 24 hr. Apoptosis was determined by Annexin V staining and flow cytometry. N = 2, data are presented as mean±SE, with triplicate
determination. (e) Effect of 8‐Cl‐Ado on cell cycle distribution in MV4–11, MOLM‐14, and KG‐1a cells. Cells (2 × 105 cells/ml) were treated with
vehicle control, 300 nM or 1 µM of 8‐Cl‐Ado for the indicated times. Flow cytometric cell cycle analysis (propidium iodide staining) was
performed 24 hr after treatment and presented as bar graphs. N = 2 (representative results from one out of two independent experiments
shown). Asterisk indicates significantly different based on unpaired t test analysis. 8‐Cl‐Ado: 8‐chloro‐adenosine; AML: acute myeloid leukemia;
DMSO: dimethyl sulfoxide; SE: standard error; WT: wild‐type [Color figure can be viewed at wileyonlinelibrary.com]
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highest sensitivity to 8‐Cl‐Ado, as quantified by DSS, an algorithm
based on continuous modeling and integration of multiple dose‐
response relationships (Figure 2a, lower panel; Yadav et al., 2014).
To test the antileukemic activity of 8‐Cl‐Ado in vivo, we injected
luciferase‐expressing FLT3‐ITD+ MOLM‐14 AML cells into im-
munodeficient NOD scid Ɣ (NSG) mice. Mice were treated with
50 mg·kg‒1·day‒1 8‐Cl‐Ado for 16 days, starting 3 days after AML
cell injection. Tumor growth was monitored by bioluminescence
imaging. We observed significant antileukemic activity by 8‐Cl‐
Ado in treated mice, in contrast to vehicle‐treated controls 16 days
after the start of treatment (p < 0.01; Figure 2b). Interestingly,
treatment of primary FLT3‐ITD + AML blasts with 8‐Cl‐Ado as low
as 5 µM for 24 hr resulted in a significantly higher level of
apoptosis induction in the more primitive CD34+ CD38‒ cells
(typically LSC‐enriched subpopulation) compared with CD34+
CD38+ cells, normal HSCs, or vehicle‐treated controls (p < 0.05;
Figure 2c). Colony forming activity was significantly reduced in
both 8‐Cl‐Ado‐treated CD34+ CD38‒ and CD34+ CD38+ cells after
the first plating (p < 0.0001) and completely eliminated after the
second plating (p < 0.05; Figure 2d). Rag2/γC mice engrafted with
FLT3‐ITD+ AML primary blast cells pretreated with 8‐Cl‐Ado
(5 μM, 24 hr) also survived significantly longer than controls
engrafted with vehicle‐treated blasts (median survival: 66 vs. 39
days; p = 0.0004; Figure 2e).
3.3 | 8‐Cl‐Ado induces DNA damage and apoptosis
in FLT3‐ITD+ AML
Treatment with 8‐Cl‐Ado resulted in increased DNA damage
pathway signaling and apoptosis induction in the FLT3‐ITD+
MV4–11 cell line and in FLT3‐ITD+ primary AML blast cells
but not in FLT3 WT KG‐1a cells and FLT3 WT primary AML
blasts, as demonstrated by changes in levels of γ‐H2AX, 53BP1,
p53, p21, and proliferating cell nuclear antigen (PCNA) protein
F IGURE 2 Effects of 8‐Cl‐Ado on primary FLT3‐ITD+ AML cells in vitro and in vivo. (a) Drug sensitivity scoring (DSS) responses across
molecularly characterized primary AML patient samples ex vivo after 72 hr exposure to 8‐Cl‐Ado. DSS was determined as previously described
(Yadav et al., 2014). Top panel: Significant AML mutations and recurrent gene fusions in red. Bottom panel: AML and control sample responses
(5 × 105 cells/ml). N = 1. (b) Effects of 8‐Cl‐Ado on tumor formation in vivo. MOLM‐14‐Luc cells (2.5 × 106) were intravenous injected in NSG mice
3 days before subcutaneous surgical implantation of an osmotic infusion pump releasing control vehicle or 8‐Cl‐Ado at 50mg·kg‒1·day‒1. Leukemia
growth was determined 16 days after the start of treatment using bioluminescence imaging (*p <0.01). N= 6 mice per group, data
are presented as mean±SE. (c and d) 8‐Cl‐Ado treatment inhibits leukemia stem cells (LSC)‐enriched subpopulations of AML blasts.
(c) CD34+/CD38− and CD34+/CD38+ subpopulations were isolated from peripheral blood mononuclear cells of a healthy donor or an AML patient
and treated with 5 μM 8‐Cl‐Ado or control for 24 hr (2 × 105 cells/ml). Apoptosis was measured using Annexin V and flow cytometry, N =2, data are
presented as mean±SE, with triplicate determination. (d) LSC subpopulations (2 × 105 cells/ml) from an AML patient were treated with 5 μM 8‐Cl‐Ado
24 hr before plating on methylcellulose. After 14 days, colonies were counted, and half of the cells were replated for an additional 14 days. N = 2, data
are presented as mean±SE, with triplicate determination. (e) 8‐Cl‐Ado pretreated (5 μM), or untreated primary FLT3‐ITD+ AML blasts (107) were
transplanted into sublethally irradiated 4‐day‐old Rag2/γC double knockout mice, and survival was determined. N =5–7 mice per group. The log‐rank
test was used to compare the survival distributions of the different treatment groups. Asterisk indicates significantly different based on unpaired t
test analysis. 8‐Cl‐Ado: 8‐chloro‐adenosine; AML: acute myeloid leukemia; DMSO: dimethyl sulfoxide; ns: not significant; SE: standard error [Color
figure can be viewed at wileyonlinelibrary.com]
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levels, as well as markers of DNA fragmentation and apoptosis
(Figure 3a−c).
3.4 | 8‐Cl‐Ado inhibits miR‐155 which is associated
with induction of SHIP1, downregulation of AKT,
activation of Ebp1, and enhanced p53/PCNA
promoter binding, followed by growth inhibition and
apoptosis, in FLT3‐ITD+ AML
As 8‐Cl‐Ado is incorporated into RNA, we reasoned that it should
also target short noncoding RNA species such as miRNA. We and
others have reported the correlation of FLT3‐ITD with high
expression of miR‐155, which contributes to the leukemogenic
activity of the mutant protein (Khalife et al., 2015). Consistent with
our hypothesis, we demonstrated a significant decrease in miR‐155
levels in 8‐Cl‐Ado‐treated FLT3‐ITD+ blast cells (Figure 4a
and S2A). This effect appeared to be specific to miR‐155, as no
changes were observed in the levels of miR‐125b, which is also
upregulated in FLT3‐ITD+ blast cells (Figure S2B). Colocalization of
8‐Cl‐Ado and miR‐155, shown by fluorescence‐labeled 8‐Cl‐Ado
(8‐Cl‐Ado‐FAM) and miR‐155 staining with SmartFlare probes
(Figure 4b), supported a direct interaction of 8‐Cl‐Ado with
miR‐155 and in turn drug‐dependent miR‐155 degradation. The
use of 8‐Cl‐Ado‐FAM led to induction of apoptosis similarly to the
unlabeled compound (Figure S2C). Overexpression of miR‐155
reversed 8‐Cl‐Ado‐induced apoptosis in MV4–11 cells (Figures 4c
and S2D), supporting miR‐155 as a relevant target for 8‐Cl‐Ado
antileukemic activity. Suppression of miR‐155 by 8‐Cl‐Ado was
associated with upregulation of SHIP1, a phosphatase that
negatively regulates AKT phosphorylation and signaling, and
decreased p‐AKT (Ser473) levels (Figures 4a, right and S2A, right).
Of note, we also observed disruption of interaction of AKT and
ErbB3 binding protein (Ebp1), a highly expressed protein in AML
(Nguyen, Zhu, Lee, Ta, & Mitchell, 2016), which regulates p53
expression and is required for preventing DNA fragmentation and
apoptosis (Figure 4d; Ahn et al., 2006; D. Q. Nguyen et al., 2015;
L. X. T. Nguyen et al., 2018).
In contrast to Ebp1 WT mouse embryonic fibroblasts (MEF),
Ebp1‐null MEF (Ebp1−/−) present with elevated p53 protein levels
(Figure S3A, left; Nguyen et al., 2015). The binding of p53 protein
to the PCNA promoter regulates PCNA transcription through
inhibition of acetyl‐histone H4 (H4Ac) binding to the transcrip-
tion site of the PCNA promoter (Figure S3b; Shan, Xu, Zhuo,
Morris, & Morris, 2003). A significant increase in p53 binding,
decrease in H4Ac binding to the PCNA promoter, and reduced
PCNA transcription was detected in MEF Ebp1−/− cells using
western blot analysis, q‐PCR and ChIP assays (Figure S3A).
Re‐expression of Ebp1 in MEF Ebp1−/− cells effectively reversed
the Ebp1 knockdown (KD) effects on p53‐regulated PCNA
transcription (Figure S3C). Consistent with these results, we
demonstrated that Ebp1 KD in primary FLT3‐ITD+ blasts resulted
in increased p53 expression (Figure 4e, left), increased p53‐PCNA
promoter binding and decreased H4Ac‐PCNA promoter binding
(Figure S4A, bottom). Subsequently, there was also an increase
in DNA fragmentation and apoptosis (Figures 4e and S4A, top)
and a decrease in PCNA messenger RNA (Figure 4f, left) and
F IGURE 3 Effects of 8‐Cl‐Ado on DNA damage signaling in FLT3‐ITD+ and FLT3 WT AML cells. (a and b) Effect of 8‐Cl‐Ado on γH2AX,
53BP1, p53, and p21 protein expression in FLT3‐ITD+ and FLT3 WT AML cells. (a) MV4–11 (FLT3‐ITD+) and KG‐1a (FLT3 WT) cells
(2 × 105 cells/ml) were treated with 500 nM 8‐Cl‐Ado for up to 39 hr before measurement and quantification of double‐strand DNA breaks as
indicated by a number of γH2AX and 53BP1 foci. N = 3. (b) Primary FLT3‐ITD+ AML blasts (a mixture of 2 × 105 cells/ml from five patients) were
treated with 500 nM 8‐Cl‐Ado or control for 24 hr, stained with indicated antibodies, and subjected to confocal microscopy. N = 2
(representative images from one out of two independent experiments shown). (c) Effects of 8‐Cl‐Ado on apoptosis of FLT3 WT and FLT3‐ITD+
primary AML blasts. A mixture of cells (2 × 105 cells/ml, from five patients) was treated with 500 nM 8‐Cl‐Ado for 24 hr, followed by genomic
DNA fragmentation analysis (left panel), Annexin V apoptosis measurement by flow cytometry (middle panel) and immunoblot as indicated
(right panel). N = 2, data are presented as mean±SE, with triplicate determination for apoptosis assay. Asterisk indicates significantly different
based on unpaired t test analysis. 8‐Cl‐Ado: 8‐chloro‐adenosine; AML: acute myeloid leukemia; DAPI: 4′,6‐diamidino‐2‐phenylindole;
SE: standard error; WT: wild‐type [Color figure can be viewed at wileyonlinelibrary.com]
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protein levels (Figure 4e, left) and decrease in colony formation
activity (Figures 4f, right and S4A, middle). Although Ebp1
overexpression did not restore miR‐155 levels, it rescued cells
from 8‐Cl‐Ado‐induced apoptosis and enhanced PCNA levels
and colony formation activity (Figures 4g and S4B), thereby
suggesting that decreased 8‐Cl‐Ado‐dependent p‐AKT levels
are an important step in the antileukemic activity of this
compound. Indeed, overexpression of a constitutive active form
of Akt (Akt‐myr) rescued cells from 8‐Cl‐Ado‐induced apoptosis
(Figure S4C).
F IGURE 4 Effects of 8‐Cl‐Ado on apoptosis and proliferation of FLT3‐ITD+ AML cells through regulation of miR‐155 and Ebp1 protein.
(a) Effect of 8‐Cl‐Ado on miR‐155 expression in FLT3‐ITD+ primary AML cells. FLT3‐ITD+ AML blast cells (mixture of 2 × 105 cells/ml from
five patients) were treated with 500 nM 8‐Cl‐Ado for 24 hr, followed by miR‐155 staining using SmartFlare probes (left panel, representative
results from one out of two independent experiments shown), q‐PCR of miR‐155 (middle panel) and immunoblot as indicated (right panel).
N = 2, data are presented as mean±SE, with triplicate determination for q‐PCR assay. (b) Colocalization of miR‐155 and 8‐Cl‐Ado in
FLT3‐ITD+ primary AML blasts. Cells (a mixture of 2 × 105 cells/ml from five patients) were incubated with FAM‐conjugated 8‐Cl‐Ado and
SmartFlare probes specific for miR‐155, followed by confocal microscopy and colocalization analysis (Zeiss, colocalization shown in cyan).
N = 2, representative images from one out of two independent experiments shown. (c) Effect of miR‐155 expression on 8‐Cl‐Ado‐induced
apoptosis of MV4–11 cells. Cells (2 × 105 cells/ml) were transfected with vector control or BIC‐155 (long noncoding RNA containing
miR‐155 sequence) and treated with 500 nM 8‐Cl‐Ado for 24 hr. Left, the percentage of apoptosis. Middle, genomic DNA fragmentation.
Right, levels of miR‐155 RNA expression. N = 2, data are presented as mean±SE, q‐PCR and apoptosis in triplicate. (d) Effects of 8‐Cl‐Ado on
AKT/Ebp1 interaction in FLT3‐ITD+ primary AML blasts. A mixture of 2 × 105 cells/ml from five patients was treated with or without 500 nM
8‐Cl‐Ado for 24 hr before immunoprecipitation with anti‐Ebp1 and immunoblotting with anti‐AKT antibodies. N = 1. (e and f) Effects of Ebp1
knockdown on apoptosis and proliferation of FLT3‐ITD+ primary AML blasts. A mixture of 2 × 105 cells/ml from five patients was transfected
with 50 nM of scrambled control (siSCR) or siEbp1 for 36 hr. (e) Left, immunoblot with antibodies as indicated. Middle, genomic DNA
fragmentation. Right, the percentage of apoptosis. N = 1, data are presented as mean±SE, apoptosis assay with triplicate determination.
(f) Left, PCNA messenger RNA expression. Right, colony formation. N = 1, data are presented as mean ±SE, with triplicate determination.
(g) Effects of Ebp1 overexpression on 8‐Cl‐Ado‐induced apoptosis and proliferation in MV4–11 cells. Cells (2 × 105 cells/ml) were
transfected with vector control or GFP‐Ebp1 for 12 hr followed by 24 hr‐treatment with 500 nM 8‐Cl‐Ado. Left to right, immunoblot with
antibodies as indicated; miR‐155 RNA expression levels; percentage of apoptosis; colony formation; q‐PCR of PCNA. N = 1, data are
presented as mean±SE, with triplicate determination. Asterisk indicates significantly different based on unpaired t test analysis.
8‐Cl‐Ado: 8‐Chloro‐adenosine; AML: acute myeloid leukemia; DAPI: 4′,6‐diamidino‐2‐phenylindole; DMSO: dimethyl sulfoxide; GADPH:
glyceraldehyde‐3‐phosphate dehydrogenase; q‐PCR: quantitative polymerase chain reaction; SE: standard error; WT: wild‐type [Color figure
can be viewed at wileyonlinelibrary.com]
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3.5 | 8‐CL‐Ado synergizes with the FLT3 inhibitor
AC220 (quizartinib) in FLT3‐ITD+ AML
We next examined the effects of the combination of 8‐Cl‐Ado with
AC220 (quizartinib), a TKI, in FLT3‐ITD+ AML cells. Compared to either
drug alone, combination treatment was more effective in decreasing
miR‐155 and p‐AKT expression, in increasing p53 protein levels and in
inhibiting PCNA transcription by p53, as well as in inhibiting colony
formation and proliferation and increasing induction of apoptosis in
FLT3‐ITD+ AML cells (Figures 5a−c and S5A−D). Finally, NSG mice
engrafted with FLT3‐ITD+ MV4–11 cells survived significantly longer
when treated with the combination of 8‐Cl‐Ado (75mg·kg‒1·day‒1;
osmotic pump) and AC220 (1mg·kg‒1·day‒1, daily oral), as compared
with single‐agent or vehicle control treatment (Figure 5d).
4 | DISCUSSION
We here report the in vitro and in vivo antileukemic activity of
the ribose‐containing, RNA‐directed nucleoside 8‐Cl‐Ado, which
appears to spare normal HSCs. Among AML molecular subtypes,
the more pronounced impact of 8‐Cl‐Ado in FLT3‐ITD+ blasts may
F IGURE 5 Effects of 8‐Cl‐Ado plus AC220 combination treatment on FLT3‐ITD+ AML cells in vitro and in vivo. (a and b) Combination
treatment with AC220 and 8‐Cl‐Ado and its effects on apoptosis and proliferation of FLT3‐ITD+ primary AML blasts. A mixture of FLT3‐ITD+
cells (2 × 105 cells/ml from five patients) was treated for 24 hr with 0.5 nM AC220, 500 nM 8‐Cl‐Ado, or both. (a) Left, immunoblot with
antibodies as indicated. Right, DNA fragmentation. N = 1. (b) miR‐155 RNA expression (left), PCNA messenger RNA expression (middle), colony
formation (right). N = 2, data are presented as mean±SE, with triplicate determination. (c) Synergistic effect of AC220 and 8‐Cl‐Ado on the
growth of FLT3‐ITD+ MV4–11 AML cells. Cells (2 × 105 cells/ml) were cultured for 72 hr with constant ratios of AC220 and 8‐Cl‐Ado, based on
previously established IC50 values, as indicated, followed by MTS assay. The synergy between AC220 and 8‐Cl‐Ado was analyzed using
CalcuSyn program. Combination indices (CI) for effective doses (ED) were: CI = 0.81 (ED50), CI = 0.77 (ED75), CI = 0.78 (ED90), and CI = 0.79
(ED95). N = 2, data are presented as mean±SE, with quadruplicate determination. (d) MV4–11‐Luc cells (5 × 106) were intravenously injected in
NSG mice 3 days before subcutaneous implantation of an osmotic infusion pump releasing 8‐Cl‐Ado at 75mg·kg‒1·day‒1 for 16 days. Daily oral
treatment with 1mg/kg AC220 or control solution was initiated at the same day the osmotic pump was implanted. Sixteen days after
implantation of the 8‐Cl‐Ado‐releasing osmotic pumps, the pumps were removed, and all treatment was stopped. Survival was quantified using
the log rank test. N = 6 animals per group. Asterisk indicates significantly different based on unpaired t test analysis. 8‐Cl‐Ado:
8‐Chloro‐adenosine; AML: acute myeloid leukemia; GADPH: glyceraldehyde‐3‐phosphate dehydrogenase; SE: standard error; WT: wild‐type
[Color figure can be viewed at wileyonlinelibrary.com]
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be achieved through previously unidentified targeting of anti-
apoptotic mechanisms involving miR‐155 and Ebp1 proteins
(Figure 6). Our data support a mechanism where 8‐Cl‐Ado
decreases miR‐155 expression, followed by induction of SHIP1,
dephosphorylation of AKT, and dissociation of the AKT/Ebp1
protein complex. Dissociation of AKT/Ebp1 then leads to increased
p53 binding to the PCNA promoter, which is associated with
inhibition of H4Ac binding to the transcription site of the PCNA
promoter and inhibition of cell growth and induction of apoptosis.
AC220 (quizartinib) is a selective and potent next‐generation
FLT3 kinase inhibitor with clinical antileukemic activity as single
agent in patients with relapsed/refractory AML, and is particularly
effective in those patients that harbor the FLT3‐ITD mutation
(J. Cortes et al., 2018; J. Cortes et al., 2013). It has also been shown
that AC220 can safely be combined with conventional chemotherapy
in patients with AML and that such drug combinations may be
beneficial as evidenced by recently presented data (Bowen et al.,
2013; Foran et al., 2013). Importantly, our results support a potential
synergistic activity of 8‐Cl‐Ado with TKIs, such as the FLT3 inhibitor
AC220, on FLT3‐ITD+ AML cells, in vitro and in vivo. The combined
treatment of AML cells with 8‐Cl‐Ado and AC220 further augmented
the effect of the individual drugs on activation of the proapoptotic
miR‐155/Ebp1/p53/PCNA signaling pathway.
On the basis of these encouraging results, and given the fact that
8‐Cl‐Ado as a ribose‐containing, RNA‐directed NA–possesses a unique
mechanism of action, a combination of TKI (i.e., AC220) with 8‐Cl‐Ado
may represent a potentially novel clinical approach for FLT3‐ITD AML.
A single‐agent Phase I/II clinical trial with 8‐Cl‐Ado for the treatment
of patients with relapsed or refractory AML has recently been initiated
(ClinicalTrials.gov identifier: NCT02509546).
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